MB-103 |
MB-103 |
Phase 1 Clinical |
Mustang Bio, City Of Hope National Medical Center |
Glioblastoma; Brain metastases |
Details
|
GQ-1001 |
GQ-1001 |
Phase 1 Clinical |
|
Stomach Neoplasms; Neoplasms; Breast Neoplasms |
Details
|
A-166 |
A-166 |
Phase 2 Clinical |
Sichuan Kelun Pharmaceutical Co Ltd |
Prostatic Neoplasms; Tongue Neoplasms; Uterine Cervical Neoplasms; Tonsillar Neoplasms; Laryngeal Neoplasms; Lip Neoplasms; Mouth Neoplasms; Lung Neoplasms; Colorectal Neoplasms; Bile Duct Neoplasms; Peritoneal Neoplasms; Carcinoma, Mucoepidermoid; Urologic Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Solid tumours; Urinary Bladder Neoplasms; Colonic Neoplasms; Skin Neoplasms; Salivary Gland Neoplasms; Pancreatic Neoplasms; Rare Diseases; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms; Liver Neoplasms |
Details
|
68Ga-anti-HER2 nanobodies (Universite Libre de Bruxelles) |
|
Phase 1 Clinical |
Universite Libre De Bruxelles |
Breast Neoplasms |
Details
|
anti-HER2 ADC (Pfizer) |
PF-06804103 |
Phase 1 Clinical |
Pfizer Inc |
Breast Neoplasms |
Details
|
HER2.taNK |
NK-92/5.28.z |
Phase 1 Clinical |
Nantkwest |
Glioblastoma |
Details
|
Pirotinib Hydrochloride |
KBP-5209 |
Phase 2 Clinical |
Kbp Biosciences Co Ltd |
Neoplasms; Breast Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
BVAC-B vaccine (Cellid) |
BVAC-B |
Phase 1 Clinical |
Cellid Company |
Stomach Neoplasms |
Details
|
M-802 |
M-802 |
Phase 1 Clinical |
Wuhan Yzy Biopharma |
Solid tumours; Stomach Neoplasms; Breast Neoplasms |
Details
|
Trastuzumab biosimilar (Dong-A ST/Meiji Seika Pharma) |
DA-3111; DMB-3111 |
Phase 1 Clinical |
Meiji Seika Pharma, Dong-A Pharmaceutical Co Ltd |
Stomach Neoplasms; Breast Neoplasms |
Details
|
SHR-A1201 |
SHR-A1201 |
Phase 1 Clinical |
Jiangsu Hengrui Medicine Co Ltd |
Breast Neoplasms |
Details
|
JRF-103 |
JRF103; JRF-103 |
Phase 1 Clinical |
Shenzhen Jinrui Foundation Biotechnology Co Ltd |
Solid tumours |
Details
|
Pertuzumab biosimilar (Shanghai Henlius Biotech) |
HLX-11 |
Phase 1 Clinical |
Shanghai Henlius Biotech Co Ltd |
Breast Neoplasms |
Details
|
HER2 cancer vaccine (BioLife Science) |
PEV-6; PEV-6A; IMU-131 |
Phase 2 Clinical |
Pevion Biotech |
Esophageal Neoplasms; Stomach Neoplasms; Breast Neoplasms; Gastrointestinal Neoplasms; Adenocarcinoma |
Details
|
TPIV-100 (TapImmune) |
TPIV-100 |
Phase 2 Clinical |
Mayo Clinic |
Breast Neoplasms |
Details
|
MT-5111 |
MT-5111 |
Phase 1 Clinical |
Molecular Templates |
Neoplasms |
Details
|
TAS-0728 |
TPC-107; TAS-0728 |
Phase 2 Clinical |
Taiho Pharma |
Neoplasms |
Details
|
AIP-303 |
AIP-303 |
Phase 2 Clinical |
Advanced Imaging Projects |
Breast Neoplasms |
Details
|
Disitamab Vedotin (Shijiazhuang Zhongqi Pharmaceutical) |
|
Phase 1 Clinical |
Cspc Pharmaceutical Technology (Shijiazhuang) Co Ltd |
Breast Neoplasms |
Details
|
Trastuzumab glyco-optimised (Glycotope) |
GT-Mab-7.3-GEX |
Phase 1 Clinical |
Glycotope |
Stomach Neoplasms; Neoplasms; Breast Neoplasms |
Details
|
Pertuzumab biosimilar (CTTQ) |
TQB-2440 |
Phase 3 Clinical |
Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd |
Breast Neoplasms |
Details
|
GB-235 |
GB-235 |
Phase 1 Clinical |
Genor Biopharma Co Ltd |
Breast Neoplasms |
Details
|
BMS-986186 |
FS-102; BMS-986186 |
Phase 1 Clinical |
F-Star |
Stomach Neoplasms; Breast Neoplasms |
Details
|
Recombinant anti-HER2 human monoclonal antibody-DM1 (Hisun Pharm/Mabworks Biotech) |
|
Phase 1 Clinical |
Beijing Mabworks Biotech Co Ltd, Zhejiang Hisun Pharmaceutical Co Ltd |
Breast Neoplasms |
Details
|
HER2(EQ)BBzeta/CD19 T cells (City of Hope) |
|
Phase 1 Clinical |
Mustang Bio, City Of Hope National Medical Center |
Glioma |
Details
|
RG-6194 |
RG-6194; BTRC-4017A |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Neoplasms |
Details
|
Zenocutuzumab |
MCLA-128 |
Phase 2 Clinical |
Merus |
Ovarian Neoplasms; Stomach Neoplasms; Breast Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Recombinant anti-HER2 antibody-Tub114 |
DAC-001; DX126-262 |
Phase 1 Clinical |
Hangzhou Dac Biotech Co Ltd |
Stomach Neoplasms; Breast Neoplasms |
Details
|
Recombinant anti-HER2 subdomain II humanized monoclonal antibody (Livzon Group) |
LZM-005 |
Phase 1 Clinical |
Livzon Pharmaceutical Group Inc |
Breast Neoplasms |
Details
|
SHR-1309 |
SHR-1309 |
Phase 1 Clinical |
Jiangsu Hengrui Medicine Co Ltd |
Metastatic breast cancer |
Details
|
Trastuzumab biosimilar (Hualan Biological Engineering) |
|
Phase 3 Clinical |
Hualan Genetic Engineering Co Ltd |
Stomach Neoplasms; Breast Neoplasms |
Details
|
Recombinant humanized anti-EGFR monoclonal antibody (Hisun Pharm/Mabworks Biotech) |
HS627 |
Phase 3 Clinical |
Zhejiang Hisun Pharmaceutical Co Ltd, Beijing Mabworks Biotech Co Ltd |
Breast Neoplasms |
Details
|
Trastuzumab biosimilar (BioIntegrator) |
BI-Mab-03 |
Phase 1 Clinical |
Biointegrator |
Breast Neoplasms |
Details
|
Tarloxotinib Bromide |
PR-610; TH-4000; SN-33999 |
Phase 2 Clinical |
Threshold |
Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Trastuzumab duocarmazine |
SYD-985 |
Phase 3 Clinical |
Synthon |
Stomach Neoplasms; Breast Neoplasms; Endometrial Neoplasms |
Details
|
BAT-8001 |
BAT-8001 |
Phase 3 Clinical |
Bio-Thera Solutions Ltd |
Solid tumours; Breast Neoplasms |
Details
|
Lapuleucel-T |
BA-7072; DN-2402; APC-8024 |
Phase 2 Clinical |
Dendreon Uk Ltd |
Carcinoma, Transitional Cell; Urogenital Neoplasms |
Details
|
HER.CAR-CMV-specific-CTLs |
HER.CAR-CMV-specific-CTLs |
Phase 1 Clinical |
Baylor College Of Medicine |
Glioblastoma |
Details
|
TAA-013 |
TAA-013 |
Phase 3 Clinical |
Tot Biopharm Co Ltd |
Breast Neoplasms |
Details
|
Pertuzumab biosimilar(SL Pharma/Combio) |
|
Phase 1 Clinical |
Beijing Sl Pharmaceutical Co Ltd, Beijing Kangming Bio New Drug Development Co Ltd |
Inflammatory Breast Neoplasms; Breast Neoplasms; Metastatic breast cancer |
Details
|
Trastuzumab biosimilar (BioXpress Therapeutics) |
BX-2318 |
Clinical |
Bioxpress Therapeutics Sa |
Breast Neoplasms |
Details
|
Recombinant anti-HER2 antibody (Anke Biotech) |
|
Phase 3 Clinical |
Anhui Anke Biotechnology (Group)Co Ltd |
Breast Neoplasms |
Details
|
Recombinant anti-HER2 humanized monoclonal antibody (Shanghai Institute of Biological Products) |
SIBP-01 |
Phase 3 Clinical |
Shanghai Institute Of Biological Products Co Ltd |
Stomach Neoplasms; Breast Neoplasms |
Details
|
Recombinant humanized anti-HER2 antibody (Hisun Pharma) |
|
Phase 3 Clinical |
Zhejiang Hisun Pharmaceutical Co Ltd |
Breast Neoplasms |
Details
|
Multi-epitope HER2 peptide vaccine (Mayo Clinic) |
|
Phase 1 Clinical |
Mayo Clinic |
Breast Neoplasms |
Details
|
Hemay-022 |
Hemay-022 |
Phase 1 Clinical |
Tianjin Hemei Pharmaceutical Technology Co Ltd, Xiajiang Hemei Pharmaceutical Co Ltd |
Breast Neoplasms |
Details
|
14C-labeled poziotinib |
|
Phase 1 Clinical |
Spectrum Pharmaceuticals |
Neoplasms |
Details
|
AMX-3009 Maleate |
AMX-3009; AMX3009马来酸 |
Phase 1 Clinical |
Anrun Medicine Technology (Suzhou) Co Ltd |
Solid tumours; Stomach Neoplasms; Pancreatic Neoplasms; Breast Neoplasms |
Details
|
[89Zr]-Df-Trastuzumab |
|
Phase 1 Clinical |
University Of Alabama At Birmingham |
Breast Neoplasms |
Details
|
LCB14-0110 |
FS-1502; LCB14-0110 |
Phase 1 Clinical |
Legochembio |
Solid tumours; Stomach Neoplasms; Breast Neoplasms |
Details
|
Trastuzumab conjugate (BioIntegrator) |
BI-CON-02 |
Phase 1 Clinical |
Biointegrator |
Breast Neoplasms |
Details
|
IBPM003TZ (Inbiopro Solutions) |
IBPM-003TZ |
Clinical |
Inbiopro Solutions |
Breast Neoplasms |
Details
|
Recombinant anti-HER2 humanized monoclonal antibody-DM1 (Qilu Pharmaceutical) |
|
Phase 1 Clinical |
Qilu Pharmaceutical Co Ltd |
Breast Neoplasms |
Details
|
Trastuzumab biosimilar (Alteogen) |
ALT-02; ALT-L2; ALT-LS2 |
Phase 3 Clinical |
Alteogen |
Stomach Neoplasms; Esophageal Neoplasms; Breast Neoplasms |
Details
|
trastuzumab biosimilar (Hetero) |
Ado-Trastuzumab biosimilar (Hetero) |
Phase 3 Clinical |
Hetero Drugs |
Neoplasms |
Details
|
Varlitinib Ditosylate |
QBT-01; ARRY-543; SPS-4370; ASLAN-001; ARRY-334543 |
Phase 3 Clinical |
Array Biopharma |
Biliary Tract Neoplasms; Neoplasms; Pancreatic Neoplasms; Bile Duct Neoplasms |
Details
|
PB-357 |
PB-357 |
Phase 1 Clinical |
Pfizer Inc |
Neoplasms |
Details
|
AU-105 |
AU-105 |
Phase 2 Clinical |
Aurora Biopharma |
Glioblastoma |
Details
|
Allitinib Tosylate |
AST-6; ALS-1306; AST-1306 |
Phase 2 Clinical |
Shanghai Allist Pharmaceutical Technology Co Ltd |
Breast Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
IBI315 |
IBI315; IBI-315 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd, Hanmi Pharmaceutical Co Ltd |
Neoplasms |
Details
|
AU-101 |
AU-101 |
Phase 2 Clinical |
Aurora Biopharma |
Glioblastoma; Osteosarcoma; Breast Neoplasms |
Details
|
ADXS-31164 |
ADXS-HER2; ADXS-31164; ADXS-cHER2; ADXS31-164 |
Phase 2 Clinical |
University Of Pennsylvania |
Osteosarcoma |
Details
|
Multiple 4SCAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) |
|
Phase 2 Clinical |
Shenzhen Geno-Immune Medical Institute |
Breast Neoplasms |
Details
|
Anti-HER2 monoclonal antibody-MCC-DM1 conjugate (Shanghai Pharma) |
B-003 (Shanghai Pharma) |
Phase 1 Clinical |
Shanghai Pharmaceuticals Holding Co Ltd, Shanghai Crosslink Pharmaceutical R & D Co Ltd |
Breast Neoplasms |
Details
|
ARX-788 |
ARX-788 |
Phase 3 Clinical |
Ambrx |
Stomach Neoplasms; Breast Neoplasms |
Details
|
IBPM002BZ (Inbiopro Solutions) |
IBPM-002BZ |
Clinical |
Inbiopro Solutions |
Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms |
Details
|
Autologous-HER2-specific-T-cells |
Autologous-HER2-specific-T-cells |
Phase 1 Clinical |
Baylor College Of Medicine |
Sarcoma |
Details
|
XMT-1522 |
TAK-522; XMT-1522 |
Phase 1 Clinical |
Mersana Therapeutics, Adimab |
Stomach Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
TGFBeta-resistant-HER2-EBV-CTLs |
TGFBeta-resistant-HER2-EBV-CTLs |
Phase 1 Clinical |
Baylor College Of Medicine |
Neoplasms |
Details
|
Recombinant anti-HER2 humanized monoclonal antibody complex |
B-002 |
Phase 1 Clinical |
Shanghai Pharmaceuticals Holding Co Ltd |
Breast Neoplasms |
Details
|
Epertinib |
S-222611 |
Phase 2 Clinical |
Shionogi & Co Ltd |
Neoplasms |
Details
|
ETBX-021 |
ETBX-021 |
Phase 2 Clinical |
Nantbioscience, Etubics Corporation |
Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Autologous AdHER2 dendritic cell vaccine (National Cancer Institute) |
|
Phase 1 Clinical |
National Cancer Institute |
Neoplasms |
Details
|
99m-Tc labeled anti-HER2 single domain antibody (NanoMab) |
99mTc-NM-02 |
Phase 1 Clinical |
Nanomab Technology Ltd |
Breast Neoplasms |
Details
|
KSP-QRH-E3-IRDye800 |
|
Phase 1 Clinical |
University Of Michigan |
Cholangiocarcinoma |
Details
|
Sapitinib |
AZD-8931 |
Phase 2 Clinical |
Astrazeneca Pharmaceutical Co Ltd |
Breast Neoplasms; Colorectal Neoplasms; Neoplasm Metastasis |
Details
|
Trastuzumab biosimilar (BIOCND/Genor Biopharma) |
GB-221 |
Phase 3 Clinical |
Genor Biopharma Co Ltd |
Breast Neoplasms |
Details
|
BCD-147 |
BCD-147 |
Phase 1 Clinical |
Biocad |
|
Details
|
MRG-002 |
MRG-002 |
Phase 2 Clinical |
Shanghai Miracogen Inc |
Stomach Neoplasms; Esophageal Neoplasms |
Details
|
HER2/neu peptide vaccine (Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium) |
|
Phase 2 Clinical |
Fred Hutchinson/University Of Washington Cancer Consortium |
Breast Neoplasms |
Details
|
Trastuzumab biosimilar (CTTQ Pharma) |
TQ-B211 |
Phase 3 Clinical |
Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd |
Stomach Neoplasms; Breast Neoplasms |
Details
|
Recombinant anti-HER2 domain II humanized monoclonal antibody (Qilu Pharmaceutical) |
|
Phase 1 Clinical |
Qilu Pharmaceutical Co Ltd |
Breast Neoplasms |
Details
|
MP-0274 |
DARPin-41; SPA-28; CME-114; CME-115; CME-118; CME-119; MP-0274 |
Phase 1 Clinical |
Molecular Partners Ag |
Neoplasms |
Details
|
DZD-9008 |
DZD-9008 |
Phase 2 Clinical |
Dizal (Jiangsu) Pharmaceutical Co Ltd |
Leukemia; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung |
Details
|
Recombinant anti-HER2 humanized monoclonal antibody (Shenzhen Main Luck Pharmaceuticals) |
|
Phase 1 Clinical |
Shenzhen Main Luck Pharmaceuticals Inc |
Breast Neoplasms |
Details
|
NJH-395 |
NJH-395 |
Phase 1 Clinical |
Novartis Pharma Ag |
Neoplasms |
Details
|
Sirotinib Maleate |
XZP-5491 |
Phase 1 Clinical |
Kbp Biosciences Co Ltd |
Stomach Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung |
Details
|
AE-37/GP-2 vaccine |
AE-37 (Generex Biotechnology Corporation) |
Phase 2 Clinical |
Generex Biotechnology Corp |
Triple Negative Breast Neoplasms; Breast Neoplasms; Prostatic Neoplasms |
Details
|
CIDeCAR |
|
Phase 1 Clinical |
Bellicum Pharmaceuticals, National Cancer Institute |
Osteosarcoma |
Details
|
Anti-HER2 small molecule imaging agent (Affibody) |
ABY-002; ABY-025; ABY-0125; 68GaABY025 |
Phase 3 Clinical |
Affibody |
Breast Neoplasms |
Details
|
Anti-HER2 CAR T-cell therapy (Seattle Children's Hospital) |
|
Phase 1 Clinical |
Seattle Children'S Research Institute |
Central Nervous System Neoplasms |
Details
|
ALT-P7 |
ALT-P7; HM2-MMAE |
Phase 1 Clinical |
Alteogen |
Stomach Neoplasms; Breast Neoplasms |
Details
|
MBS-301 |
MBS-301 |
Phase 1 Clinical |
Beijing Mabworks Biotech Co Ltd |
Stomach Neoplasms; Breast Neoplasms |
Details
|
Anti-CD3 and anti-HER2 BiTE-expressing T cell (MedImmune) |
|
Phase 2 Clinical |
University Of Michigan, Huazhong University Of Science And Technology, Medimmune, University Of Virginia Cancer Center |
Breast Neoplasms |
Details
|
KSP-910638-G |
KSP-910638G; KSP-910638-G |
Phase 1 Clinical |
University Of Michigan |
Gastrointestinal Neoplasms |
Details
|
HLX-22 |
AC-101; HLX-22 |
Phase 1 Clinical |
|
Stomach Neoplasms; Breast Neoplasms |
Details
|
GB-251 |
GB-251 |
Phase 1 Clinical |
Genor Biopharma Co Ltd |
Breast Neoplasms |
Details
|
Trastuzumab biosimilar (EirGenix) |
EG-12014 |
Phase 3 Clinical |
Eirgenix |
Breast Neoplasms |
Details
|
普维替尼 |
|
Phase 1 Clinical |
Suzhou Teligene Ltd |
Neoplasms |
Details
|
KN-026 |
KN-026 |
Phase 2 Clinical |
Suzhou Alphamab Co Ltd |
Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma; Breast Neoplasms |
Details
|
MX-402 |
MX-402 |
Phase 1 Clinical |
Medvax Technologies |
Stomach Neoplasms |
Details
|
Trastuzumab biosimilar (Tanvex Biopharma) |
TX-05 |
Phase 3 Clinical |
Tanvex Biopharma |
Breast Neoplasms |
Details
|
Trastuzumab biosimilar (NeuClone/Serum Institute of India) |
|
Phase 1 Clinical |
Serum Institute Of India, Neuclone |
Stomach Neoplasms; Breast Neoplasms |
Details
|
RG-6148 |
RG-6148; DHES-0815A |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Breast Neoplasms |
Details
|
BDTX-189 |
BDTX-189 |
Phase 2 Clinical |
Black Diamond Therapeutics |
Neoplasms |
Details
|
DP-303c |
DP303c; DP-303c |
Phase 1 Clinical |
Cspc Pharmaceutical Technology (Shijiazhuang) Co Ltd |
Neoplasms |
Details
|
Trastuzumab biosimilar |
CMAB-809 |
Phase 1 Clinical |
Taizhou Maibo Taike Biotechnology Co Ltd |
Breast Neoplasms |
Details
|
Tesevatinib |
KD-019; KD-020; XL-647; EXEL-7647 |
Phase 3 Clinical |
Exelixis Inc |
Glioblastoma; Breast Neoplasms; Brain Neoplasms; Polycystic Kidney, Autosomal Dominant; Brain metastases; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Polycystic Kidney, Autosomal Recessive |
Details
|
Dual-targeting HER2 and PD-L1 CAR-T Cell Therapy (Sichuan University) |
|
Phase 1 Clinical |
Sichuan University |
Peritoneal Neoplasms |
Details
|
AP-32788 |
TAK-788; AP-32788 |
Phase 3 Clinical |
Takeda Pharmaceutical Co Ltd, Ariad Pharmaceuticals Inc, Millennium Pharmaceuticals Inc |
Kidney Diseases; Hepatic Insufficiency; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
GBR-1302 |
GBR-1302; HBM-9302 |
Phase 2 Clinical |
Glenmark Pharmaceuticals Ltd |
Breast Neoplasms |
Details
|
Larotinib Mesylate |
Z-650 |
Phase 3 Clinical |
Guangdong Dongyangguang Pharmaceutical Co Ltd |
Solid tumours; Esophageal Neoplasms; Pancreatic Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell |
Details
|
ZW-49 |
ZW-49 |
Phase 1 Clinical |
Zymeworks Inc |
Stomach Neoplasms; Neoplasms; Breast Neoplasms |
Details
|
Poziotinib |
NOV1201; HM-78136; HM-78136B; NOV-120101 |
Phase 2 Clinical |
Hanmi Pharmaceutical Co Ltd |
Solid tumours; Head and Neck Neoplasms; Stomach Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Glioma; Carcinoma, Non-Small-Cell Lung |
Details
|
Zanidatamab |
ZW-25 |
Phase 2 Clinical |
Zymeworks Inc |
Biliary Tract Neoplasms; Ovarian Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Bile Duct Neoplasms; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Uterine Cervical Neoplasms |
Details
|
Recombinant human ErbB3 fragment vaccine (Zensun) |
rhErbB3-f |
Phase 1 Clinical |
Zensun (Shanghai) Sci & Tech Co Ltd |
Neoplasms |
Details
|
Trastuzumab biosimilar (United BioPharma) |
UB-921 |
Phase 1 Clinical |
United Biopharma Inc |
Breast Neoplasms |
Details
|
Selatinib Ditosilate |
QLNC-120 |
Phase 2 Clinical |
Qilu Antibiotics (Linyi) Pharmaceutical Co Ltd, Qilu Pharmaceutical Co Ltd |
Stomach Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|